Quality Grind Podcast
Welcome to The Quality Grind Podcast, presented by Medvacon! Join hosts Joe Toscano, President of Medvacon, and Mike Kent, Director of Learning Platforms, as they (we) have some fun while tackling topics related to the “everyday grind” within Life Science industries.
Featuring conversations with key industry players, they’ll dive into their unique problem-solving strategies, career paths and personal interests. Most importantly, their (our) goal is to cultivate a community where information and experiences can be shared with and for the benefit of all, emphasizing the diversity of approaches to industry challenges and the importance of continuous engagement and learning.
Quality Grind Podcast
QGP Short: Compounding Pharmacies - Regulatory Landscape and Requirements
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Compounding Pharmacies – are you prepared for increased scrutiny?
With select grace periods now behind us, FDA's focus has shifted to active enforcement. Inspections and warning letters are becoming more frequent as FDA hones in on compliance with both agency registration requirements and USP compounding standards.
Today's Quality Grind Short will help you strengthen your operations, stay inspection-ready, and protect both your patients and your business.
At Medvacon, our experienced team guides compounding pharmacies through compliance challenges, helping to avoid costly issues and build confidence in your quality systems.
Don’t wait until the FDA is at your door. Call us today at 833-633-8226 or visit www.medvacon.com to make sure your operations are fully aligned with regulatory expectations.
Contact MEDVACON:
- Message us at @MedvaconLifeSciences on LinkedIn
- Visit our website at www.medvacon.com/contact
- Email us at qualitygrind@medvacon.com
Thanks for listening! Don't forget to follow us @medvacon on all platforms for updates on blogs and podcasts!
QGP Short: Requirements for Compounding Pharmacies
In October, 2012, contaminated injections from the New England Compounding Center, a large scale drug compounding facility, led to an outbreak of fungal meningitis that killed more than 60 people and injured more than 700. This outbreak brought national attention to the incomplete oversight of compounding.
Compounded drugs play a critical role when patients need treatments not available in FDA-approved forms. But how they're regulated can be confusing, and that has big implications for safety and quality. Most recently, grace periods have ended for some big players in the compounded GLP-1 drug space, returning the spotlight once again to regulation and oversight.
Let's take a closer look at the current landscape around this industry.
Traditional compounding pharmacies known as 503A, prepare medications based on a patient-specific prescription. They're primarily regulated by state Boards of Pharmacy and are exempt from FDA's pre-market approval and manufacturing standards.
503B outsourcing facilities on the other hand can compound in bulk, including office stock for hospitals and clinics. They must register with the FDA, follow GMPs - current Good Manufacturing Practices - and are subject to FDA inspections.
Despite this framework, problems remain. Some pharmacies operate at large scale under 503A instead of registering as 503B. State laws can conflict with federal rules on prescriptions, and because 503A pharmacies don't register with FDA, oversight is often reactive, triggered by complaints or adverse events.
Professional standards have long been in place as part of the United States Pharmacopeia. Specifically, USP <795> for non-sterile compounding, USP <797> for sterile compounding, and USP <800> for compounding hazardous drugs.
These standards provide minimum benchmarks for quality and safety, but enforcement varies by state. Some pharmacies also pursue voluntary accreditations for higher assurance, though this is still relatively rare.
State Boards of Pharmacy continue to play the primary role in regulating most compounding, but resources and expertise vary. Inspections may be infrequent, and oversight of physician compounding is often limited.
Both federal and state regulators are working to close gaps through joint inspections, interstate agreements and new training initiatives. Still, differences in standards and enforcement create challenges for patients and providers alike.
The takeaway?
503A pharmacies serve individual patient-specific needs, while 503B outsourcing facilities supply larger-scale demand. Both are essential, but stronger alignment is needed across state rules, federal oversight, and USP standards in order to fully protect patients. And as always, firms taking it upon themselves to be more rigorous in their operations face fewer risks than those that don't.
Is your pharmacy prepared? With the right expertise, you can strengthen your operations, stay inspection ready, and protect both your patients and your business.
At Medvacon, we help pharmacies build compliant and efficient quality systems that inspire confidence from regulators, staff, and patients alike.
Don't wait until the FDA is at your door. Lead with Quality. Call us today at (833) 633-8226 or visit www.medvacon.com to get started.